

Feasibility Assessment

Prostate Cancer – Avoidance of Overuse of Bone Scans for Staging Low Risk Prostate Cancer Patients

A 2016 feasibility assessment was performed in order to assess the extent to which the required data are readily available or could be captured without undue burden and can be implemented for performance measurement.

Two entities participated in the Feasibility assessment for this measure.

- One participating entity is a VA medical center, which serves more than 85,000 unique veterans 880,000 outpatient Veteran visits each year in the Pacific Northwest.
- The second participating entity is a 619-bed multispecialty academic medical center, serving 33 counties, in the state of California.
- Two different EHR products were included in this assessment.

Feasibility Assessment results

All data elements for this measure are captured in the Electronic Health Record, although some are unable to be entered in structured fields. Some of the value sets are being used and a small number of value sets are being substituted with organization specific codes and text, to collect information needed for measure reporting. Future iterations of vendor products will likely allow health care providers to collect the diagnosis and staging results through structured fields and will not likely require text entry. No modifications have been made to the measure, as the measure is currently feasible for implementation, as specified. Feasibility score cards and simulated test cases are attached, for review.

3b.3. Feasibility

eMeasure Title: : Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (129)			
Data Element(s): Diagnosis: Pain Related to Prostate Cancer, Prostate Cancer			
	Current	Future	Comments
	Feasible today up to 1 year	Feasible in 3- 5 years	
DATA AVAILABILITY: Is the data readily available in structured format , i.e., resides in fixed fields in EHRs?	3	3	Data element exists in structured format in EHR
DATA ACCURACY: What is the accuracy of the data element in EHRs under normal operating conditions? Are the data source and recorder specified?	3	3	The information is from the most authoritative source and is highly likely to be correct. (e.g., laboratory test results transmitted directed from the laboratory information into the EHR).
DATA STANDARDS: Is the data element coded using a nationally accepted terminology standard?	3	3	Always coded in nationally accepted standards
WORKFLOW: Is the data captured during the course of care and fits the typical EHR workflow for that user?	3	3	Requires no additional data entry from clinician solely for the quality measure and no EMR user interface changes. Data element is available as a byproduct of routine care

eMeasure Title: : Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (129)			
Data Element(s): Diagnostic Study, Performed: Bone Scan			
	Current	Future	Comments
	Feasible today up to 1 year	Feasible in 3- 5 years	
DATA AVAILABILITY: Is the data readily available in structured format , i.e., resides in fixed fields in EHRs?	3	3	Data element exists in structured format in EHR
DATA ACCURACY: What is the accuracy of the data element in EHRs under normal operating conditions? Are the data source and recorder specified?	3	3	The information is from the most authoritative source and is highly likely to be correct. (e.g., laboratory test results transmitted directed from the laboratory information into the EHR).
DATA STANDARDS: Is the data element coded using a nationally accepted terminology standard?	2	3	Standards currently available, but not widely adopted
WORKFLOW: Is the data captured during the course of care and fits the typical EHR workflow for that user?	3	3	Requires no additional data entry from clinician solely for the quality measure and no EMR user interface changes. Data element is available as a byproduct of routine care

eMeasure Title : Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (129)			
Data Element: Laboratory Test, Performed: Gleason Score, Prostate Specific Antigen Test			

	Current	Future	Comments
	Feasible today up to 1 year	Feasible in 3- 5 years	
DATA AVAILABILITY: Is the data readily available in structured format , i.e., resides in fixed fields in EHRs?	2	3	Data element is required for certified EHR, but is not available in structured format in this EHR
DATA ACCURACY: What is the accuracy of the data element in EHRs under normal operating conditions? Are the data source and recorder specified?	3	3	The information is from the most authoritative source and is highly likely to be correct. (e.g., laboratory test results transmitted directed from the laboratory information into the EHR).
DATA STANDARDS: Is the data element coded using a nationally accepted terminology standard?	2	3	Standards currently available, but not widely adopted.
WORKFLOW: Is the data captured during the course of care and fits the typical EHR workflow for that user?	2	3	Additional time and effort over and above routine care is required but some perceived to be of benefit

eMeasure Title : : Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (129)			
Data Element(s): Procedure, Performed: Cancer Staging			
	Current	Future	Comments
	Feasible today up to 1 year	Feasible in 3- 5 years	
DATA AVAILABILITY: Is the data readily available in structured format , i.e., resides in fixed fields in EHRs?	3	3	Data element is required for certified EHR, but is not available in structured format in this EHR
DATA ACCURACY: What is the accuracy of the data element in EHRs under normal operating conditions? Are the data source and recorder specified?	3	3	The information is from the most authoritative source and is highly likely to be correct. (e.g., laboratory test results transmitted directed from the laboratory information into the EHR).
DATA STANDARDS: Is the data element coded using a nationally accepted terminology standard?	2	3	Standards currently available, but not widely adopted
WORKFLOW: Is the data captured during the course of care and fits the typical EHR workflow for that user?	3	3	Requires no additional data entry from clinician solely for the quality measure and no EMR user interface changes. Data element is available as a byproduct of routine care



eMeasure Title : : Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (129)			
Data Element(s): Procedure, Performed: Prostate Cancer Treatment, Salvage Therapy			
	Current	Future	Comments
	Feasible today up to 1 year	Feasible in 3- 5 years	
DATA AVAILABILITY: Is the data readily available in structured format , i.e., resides in fixed fields in EHRs?	3	3	Data element is required for certified EHR, but is not available in structured format in this EHR
DATA ACCURACY: What is the accuracy of the data element in EHRs under normal operating conditions? Are the data source and recorder specified?	3	3	The information is from the most authoritative source and is highly likely to be correct. (e.g., laboratory test results transmitted directed from the laboratory information into the EHR).
DATA STANDARDS: Is the data element coded using a nationally accepted terminology standard?	2	3	Standards currently available, but not widely adopted
WORKFLOW: Is the data captured during the course of care and fits the typical EHR workflow for that user?	3	3	Requires no additional data entry from clinician solely for the quality measure and no EMR user interface changes. Data element is available as a byproduct of routine care

eMeasure Title : Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (129)			
Data Element(s): Attribute: Reason: Reason Documented			
	Current	Future	Comments
	Feasible today up to 1 year	Feasible in 3- 5 years	
DATA AVAILABILITY: Is the data readily available in structured format , i.e., resides in fixed fields in EHRs?	2	3	Data element is required for certified EHR, but is not available in structured format in this EHR
DATA ACCURACY: What is the accuracy of the data element in EHRs under normal operating conditions? Are the data source and recorder specified?	3	3	The information is from the most authoritative source and is highly likely to be correct. (e.g., laboratory test results transmitted directed from the laboratory information into the EHR).
DATA STANDARDS: Is the data element coded using a nationally accepted terminology standard?	2	3	Standards currently available, but not widely adopted
WORKFLOW: Is the data captured during the course of care and fits the typical EHR workflow for that user?	2	3	Additional time and effort over and above routine care is required but some perceived to be of benefit

eMeasure Title: : Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients (129)			
Data Element(s): Attribute: Result: Prostate Cancer Primary Tumor Size T2a, Prostate Cancer Primary Tumor Size T1c, Prostate Cancer Primary Tumor Size T1a, Prostate Cancer Primary Tumor Size T1b			
	Current	Future	Comments
	Feasible today up to 1 year	Feasible in 3- 5 years	
DATA AVAILABILITY: Is the data readily available in structured format , i.e., resides in fixed fields in EHRs?	2	3	Data element is required for certified EHR, but is not available in structured format in this EHR
DATA ACCURACY: What is the accuracy of the data element in EHRs under normal operating conditions? Are the data source and recorder specified?	3	3	The information is from the most authoritative source and is highly likely to be correct. (e.g., laboratory test results transmitted directed from the laboratory information into the EHR).
DATA STANDARDS: Is the data element coded using a nationally accepted terminology standard?	2	3	Standards currently available, but not widely adopted
WORKFLOW: Is the data captured during the course of care and fits the typical EHR workflow for that user?	2	3	Additional time and effort over and above routine care is required but some perceived to be of benefit

NQF 389 Bonnie Output, Screen Shots and Excel Summary

Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients

 MEASURES 

UPLOAD

EXPECTED


STATUS

TEST PATIENTS

Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging
Low Risk Prostate Cancer Patients


CMS129v6

UPDATE

 100

PASS

34 /34



BONNIE: TEST PATIENT RESULTS BY MEASURE

RESULT	CATEGORY
PASS	34 _{/34}
100%	Passing
100%	Coverage

PASS: [TESTIngrahm, Ryan](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTLightner, Otis](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTMadison, Nathan](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTCalvin, Xander](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTQuinnville, Jonathan](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTStevenson, Henry](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTTaylor, Gus](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

PASS: [TESTOlsen, Langston](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTVan Amelsvoort, Douglas](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

PASS: [TESTAbdula, Ziggy](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

PASS: [TESTDavidson, Walter](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTWest, Charles](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	1	1

PASS: [TESTLutz, Octovio](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTOsbourne, Lane](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTXiao, Bill](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	1	1

PASS: [TESTYoung, Aaron](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	1	1

PASS: [TESTDugger, Wade](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTAnasari, Bill](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

PASS: [TESTNye, Bill](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

PASS: TESTSmith, Will

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

PASS: TESTArnold, Zaden

QRDA

Status	Population	Expected	Actual
✓	IPP	0	0
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: TESTEldridge, Vincent

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTFranklin, Udi](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTPaulson, Keith](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTRonaldson, Ivan](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

PASS: [TESTBernard, Young](#)

Status	Population	Expected	Actual
✓	IPP	0	0
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTNolan, Manny](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTBirmingham, Yardley](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTClay, Xander](#)

Status	Population	Expected	Actual
✓	IPP	0	0
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTJackson, Quin](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

PASS: [TESTJameson, Quasim](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTOscar, Larry](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTChesson, Xerxes](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	0	0
✓	DENEX	0	0
✓	NUMER	0	0
✓	DENEXCEP	0	0

PASS: [TESTUnderwood, Ernest](#)

Status	Population	Expected	Actual
✓	IPP	1	1
✓	DENOM	1	1
✓	DENEX	0	0
✓	NUMER	1	1
✓	DENEXCEP	0	0

Summary of Patient Test Cases in Excel

Case	Age	Sex	Prostate Cancer Dx	PSA Test	Clinical Staging	Gleason Score	Prostate Cancer Treatment Procedure	Bone Scan	Denominator Exception	IP	Denom	Den Excl	Num	Den Exception
1	18	M	No Dx	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	None		N	N	n/a	N	N
2	20	M	Dx starts after MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Diagnostic, Study, performed: Bone scan starts after the start of Diagnosis, Active: Prostate Cancer	Procedure, Performed: Salvage Therapy starts after the start of Diagnosis, Active: Prostate Cancer	N	N	n/a	N	N
3	25	M	Dx ends before the MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	None		N	N	n/a	N	N
4	30	M	Dx ends before the prostate cancer treatment	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts after the start of Diagnosis, Active: Prostate Cancer		Y	Y	n/a	N	N

Case	Age	Sex	Prostate Cancer Dx	PSA Test	Clinical Staging	Gleason Score	Prostate Cancer Treatment Procedure	Bone Scan	Denominator Exception	IP	Denom	Den Excl	Num	Den Exception
5	35	M	Dx starts before MP; Dx ends during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure, Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason score completed during MP; Lab Test, Performed: Gleason score (result <=6)	None	None		Y	N	n/a	N	N
6	40	M	Dx starts before MP; Dx ends during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment before MP	None		Y	N	n/a	N	N
7	45	M	Dx concurrent with PSA test	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment after MP	None		Y	N	n/a	N	N
8	50	M	Dx starts during MP	Lab Test, Performed: PSA Test (result <=10ng/mL)	None	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	None		Y	N	n/a	N	N
9	55	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1b (not T2a or T1c)	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan does not start after the start of Diagnosis, Active: Prostate Cancer		Y	N	n/a	N	N

Case	Age	Sex	Prostate Cancer Dx	PSA Test	Clinical Staging	Gleason Score	Prostate Cancer Treatment Procedure	Bone Scan	Denominator Exception	IP	Denom	Den Excl	Num	Den Exception
10	60	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts after the start of Prostate Cancer Treatment; Prostate Cancer Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Diagnostic, Study, performed: Bone scan starts after the start of Diagnosis, Active: Prostate Cancer	Diagnostic study, performed: Bone scan (reason: reason documented)	Y	N	n/a	N	N
11	65	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts during Prostate Cancer Treatment; Prostate Cancer Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	None		Y	N	n/a	N	N
12	70	M	Dx starts during MP	None	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	None		Y	N	n/a	N	N
13	75	M	Dx starts during MP	Lab Test, Performed: PSA Test starts after the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan does not start after the start of Diagnosis, Active: Prostate Cancer		Y	N	n/a	N	N
14	80	M	Dx starts during MP	Lab Test, Performed: PSA Test starts during Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Diagnostic, Study, performed: Bone scan starts after the start of Diagnosis, Active: Prostate Cancer	Procedure, Performed: Salvage Therapy starts after the start of Diagnosis, Active: Prostate Cancer	Y	N	n/a	N	N

Case	Age	Sex	Prostate Cancer Dx	PSA Test	Clinical Staging	Gleason Score	Prostate Cancer Treatment Procedure	Bone Scan	Denominator Exception	IP	Denom	Den Excl	Num	Den Exception
15	85	M	Dx before MP	Lab Test, Performed: most recent PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result >10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	None		Y	N	n/a	N	N
16	90	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	None	Prostate Cancer Treatment during MP	None		Y	N	n/a	N	N
17	16	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts after the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan does not start after the start of Diagnosis, Active: Prostate Cancer		Y	N	n/a	N	N
18	18	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts during Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	None		Y	N	n/a	N	N
19	20	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: most recent Gleason Score starts before the start of Prostate Cancer Treatment; Most recent Lab Test, Performed: Gleason score (result >6)	Prostate Cancer Treatment during MP	Bone scan starts after the start of Diagnosis, Active: Prostate Cancer	Diagnosis, Active: Pain related to Prostate Cancer	Y	N	n/a	N	N

Case	Age	Sex	Prostate Cancer Dx	PSA Test	Clinical Staging	Gleason Score	Prostate Cancer Treatment Procedure	Bone Scan	Denominator Exception	IP	Denom	Den Excl	Num	Den Exception
20	25	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	None		Y	Y	n/a	Y	N
21	30	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts after the start of Diagnosis, Active: Prostate Cancer		Y	Y	n/a	N	N
22	35	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts during Diagnosis, Active: Prostate Cancer before MP		Y	Y	n/a	Y	N
23	40	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts during Diagnosis, Active: Prostate Cancer before MP		Y	Y	n/a	Y	N
24	45	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan does not start after the start of Diagnosis, Active: Prostate Cancer		Y	Y	n/a	Y	N

Case	Age	Sex	Prostate Cancer Dx	PSA Test	Clinical Staging	Gleason Score	Prostate Cancer Treatment Procedure	Bone Scan	Denominator Exception	IP	Denom	Den Excl	Num	Den Exception
25	50	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts after the start of Diagnosis, Active: Prostate Cancer	Procedure, Performed: Salvage Therapy starts after the start of Diagnosis, Active: Prostate Cancer	Y	Y	n/a	N	Y
26	55	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T2a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts after the start of Diagnosis, Active: Prostate Cancer	Diagnosis, Active: Pain Relative to Prostate Cancer starts after the start of Diagnosis, Active: Prostate Cancer	Y	Y	n/a	N	Y
27	60	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts after the start of Diagnosis, Active: Prostate Cancer	Diagnostic Study, Performed: Bone Scan (Reason Documented) starts after the start of Diagnosis, Active: Prostate Cancer	Y	Y	n/a	N	Y
28	65	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan does not start after the start of Diagnosis, Active: Prostate Cancer	Diagnosis, Active: Pain Relative to Prostate Cancer starts before start of Diagnosis, Active: Prostate Cancer	Y	Y	n/a	Y	N
29	70	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts after the start of Diagnosis, Active: Prostate Cancer	Procedure, Performed: Salvage Therapy ends before Diagnosis, Active: Prostate Cancer	Y	Y	n/a	N	N

Case	Age	Sex	Prostate Cancer Dx	PSA Test	Clinical Staging	Gleason Score	Prostate Cancer Treatment Procedure	Bone Scan	Denominator Exception	IP	Denom	Den Excl	Num	Den Exception
30	75	M	Dx before MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts after the start of Diagnosis, Active: Prostate Cancer	Diagnosis, Active: Pain Relative to Prostate Cancer ends during Diagnosis, Active: Prostate Cancer	Y	Y	n/a	N	N
31	80	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan starts after the start of Diagnosis, Active: Prostate Cancer	Diagnostic Study, Performed: Bone Scan (Reason Documented) starts during Diagnosis, Active: Prostate Cancer	Y	Y	n/a	N	N
32	41	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1b	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan does not start after the start of Diagnosis, Active: Prostate Cancer		Y	Y	n/a	Y	N
33	43	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1a	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan does not start after the start of Diagnosis, Active: Prostate Cancer		Y	Y	n/a	Y	N
34	43	M	Dx starts during MP	Lab Test, Performed: PSA Test starts before the start of Procedure, Performed: Clinical Staging Result; Lab Test, Performed: PSA test (result <=10ng/mL)	Procedure, Performed: Clinical Staging Procedure starts before the start of Prostate Cancer Treatment; Procedure, Performed: Primary Tumor Size T1c	Lab Test, Performed: Gleason Score starts before the start of Prostate Cancer Treatment; Lab Test, Performed: Gleason score (result <=6)	Prostate Cancer Treatment during MP	Bone Scan does not start after the start of Diagnosis, Active: Prostate Cancer		Y	Y	n/a	Y	N